title: [Desensitization to tipranavir caused by toxicodermia].
authors.forename: B
authors.initials: B
authors.lastname: Martínez Castro
authors.forename: R
authors.initials: R
authors.lastname: Ferrando Piqueres
authors.forename: M
authors.initials: M
authors.lastname: Martínez García
authors.forename: E
authors.initials: E
authors.lastname: Soler Company
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects*; D000069454:Darunavir; D003888:Desensitization, Immunologic; D024921:Drug Resistance, Multiple, Viral; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41; D015658:HIV Infections / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011753:Pyrones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011760:Pyrrolidinones / Q000009:adverse effects; D000068898:Raltegravir Potassium; D012008:Recurrence; D019438:Ritonavir / Q000008:administration & dosage / Q000627:therapeutic use; D013262:Stevens-Johnson Syndrome / Q000209:etiology* / Q000517:prevention & control; D013449:Sulfonamides / Q000009:adverse effects
chemical_list: D019380:Anti-HIV Agents; D015700:HIV Envelope Protein gp41; D017320:HIV Protease Inhibitors; D010446:Peptide Fragments; D011725:Pyridines; D011753:Pyrones; D011760:Pyrrolidinones; D013449:Sulfonamides; D000077560:Enfuvirtide; D019259:Lamivudine; D000068898:Raltegravir Potassium; D019438:Ritonavir; D000069454:Darunavir; C107201:tipranavir